BioSpace News Archive

Bayer said the award conflicts with an April report from the EPA that says glyphosate, the active ingredient in Roundup, is not a carcinogen.

The trial showed that the company’s auto-injector administered treatment delivered the same results as a previous trial using a pre-filled syringe.

In its first-quarter financial report, Solid Biosciences updated on its Phase I/II IGNITE DMD clinical trial. The progress was marred by adverse events.

Researchers with the RIKEN Center for Brain Science and Ochanomizu University evaluated a treatment for stroke that appears to decrease the damage to the brain. The scientists studied the approach in mice.

“With today’s FDA approval, Eylea has once again set a high bar for the treatment of diabetic eye diseases,” stated George D. Yancopoulos, president and chief scientific officer at Regeneron.

The companies said they planned to give the government additional time to review the deal. This is the third delay.

Myovant Sciences announced positive data from LIBERTY 1, one of its two Phase III trials of once daily relugolix combination therapy in uterine fibroids. The trial met its primary endpoint and six key secondary endpoints.

Under the terms of the deal, AbbVie will grant Germany-based Boehringer Ingelheim a non-exclusive license for Cyltezo, its biosimilar to Humira.

Advanced Medical Solutions Group plc (AIM: AMS), the surgical and advanced wound care specialist company, today announces that the Company has received Investigational Device Exemption (IDE) for the LiquiBand® Fix8™ device in the US.

Malin Corporation plc. (Euronext Growth Dublin:MLC) (“Malin”), a company investing in highly innovative life sciences companies, is pleased to note that Poseida Therapeutics Inc. (“Poseida”), one of Malin’s Priority Assets, has announced the US Food and Drug Administration (“FDA”) has granted orphan drug designation to P-BCMA-101 for the treatment of relapsed and/or refractory multiple myeloma.